Articles From: FBL Financial Group Declares Quarterly Dividend to FDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States


FBL Financial Group, Inc. (NYSE: FFG) today announced that its Board of Directors declared a quarterly cash dividend of $0.35 per share to owners of Class A and Class B common stock.
Sign-up for FBL Financial Group Declares Quarterly Dividend investment picks
FBL Financial Group, Inc. (NYSE: FFG): Financial Highlights (Dollars in thousands, except per share data) FBL Financial Group, Inc. (NYSE: FFG) today reported net income attributable to FBL for the second quarter of 2014 of $28.6 million, or $1.14 per diluted common share compared to $29.6 million, or $1.13 per diluted common share, for the second quarter of 2013.
Sign-up for FBL Financial Group Reports Second Quarter 2014 Results investment picks
FBL Financial Group, Inc. (NYSE:FFG) will announce its second quarter 2014 earnings after the close of the market on Thursday, July 31, 2014.
Sign-up for FBL Financial Group Schedules Second Quarter 2014 Earnings Release Date, Conference Call and Webcast investment picks
FBL Financial Group, Inc. (NYSE:FFG) today announced that Kathleen Till Stange, Corporate and Investor Relations Vice President, will present at the 2014 InvestMNt Conference sponsored by CFA Society Minnesota.
Sign-up for FBL Financial Group to Present at 2014 InvestMNt Conference investment picks
FBL Financial Group, Inc. (NYSE:FFG) today announced that Donald J.
Sign-up for FBL Financial Group to Present at Keefe, Bruyette & Woods Insurance Conference investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR & Co. Announces Final Results of Self-Tender Offer investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR & Co. Announces Preliminary Results of Self-Tender investment picks
ARLINGTON, Va., July 21, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Announces Self Tender Offer to Purchase up to One Million Shares investment picks
ARLINGTON, Va., July 24, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR & Co. Commences Self Tender Offer to Purchase Up to One Million Shares investment picks
ARLINGTON, Va., July 23, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR Announces Inaugural Healthcare Conference investment picks
ARLINGTON, Va., Aug.
Sign-up for FBR Inaugural Healthcare Conference to Feature Thought Leadership Panel Discussions investment picks
ARLINGTON, Va., July 15, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR Reports Second Quarter Financial Results investment picks
ARLINGTON, Va., July 2, 2014 (GLOBE NEWSWIRE) -- FBR & Co.
Sign-up for FBR to Report Second Quarter 2014 Financial Results investment picks
2014/8/1
FCB Financial Holdings, Inc. (formerly known as Bond Street Holdings, Inc.) (the "Company") (NYSE: FCB) announced the pricing of its initial public offering of 7,520,000 shares of Class A common stock at a public offering price of $22.00 per share.
Sign-up for FCB Financial Holdings, Inc. Announces the Pricing of Its Initial Public Offering investment picks
FCB Financial Holdings, Inc. (NYSE: FCB) announced today that the underwriters of its initial public offering of 7,520,000 shares of its common stock that closed on August 6, 2014 have partially exercised their option to purchase an additional 720,000 shares of common stock from FCB Financial Holdings, Inc. at the initial public offering price of $22.00 per share, less underwriting discounts.
Sign-up for FCB Financial Holdings, Inc. Announces Underwriters’ Exercise of Option investment picks
FCB Financial Holdings, Inc. (NYSE:FCB) (the "Company") today reported second quarter 2014 net income of $9.2 million, or $0.26 per diluted share, and core net income of $7.4 million, or $0.21 per diluted share.
Sign-up for FCB Financial Holdings, Inc. Reports Second Quarter Net Income of $9.2 Million, or $0.26 Per Diluted Share, Up 114% Year Over Year investment picks
2014/9/10
By Gautham Nagesh Wireless carriers could soon be subject to new rules on how they handle content on their networks, Federal Communications Chairman Tom Wheeler suggested in a speech to the industry on Tuesday.
Sign-up for FCC chairman: Broadband rules could cover wireless networks investment picks
Signs Business Collaboration in South Korea with Wonik Corporation Second Quarter 2014 Conference Call Friday August 15th at 9:00 am BRIDGEWATER, N.J. , Aug.
Sign-up for FDA Accepts CorMedix, Inc. Pivotal Phase 3 Study Protocol investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1133903&ProfileId=051205&sourceType=1 SAN DIEGO, CA --
Sign-up for FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe investment picks
- Toujeo dossier already accepted by EMA - PARIS , July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin.
Sign-up for FDA Accepts Sanofi's New Drug Application for Basal Insulin Toujeo® investment picks
Incyte Corporation (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) for ruxolitinib as a potential treatment of patients with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea.
Sign-up for FDA Accepts Supplemental New Drug Application for Jakafi® (ruxolitinib) and Priority Review Granted investment picks
Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter’s investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
Sign-up for FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter’s HyQvia for Primary Immunodeficiency investment picks
Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails.
Sign-up for FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails investment picks
Baxter International, Inc. (NYSE:BAX) today announced that the United States Food and Drug Administration (FDA) has approved FLEXBUMIN ® [Albumin (Human)], USP, 5% Solution.
Sign-up for FDA Approves Baxter’s FLEXBUMIN 5%, First and Only 5% Human Albumin Solution in a Flexible Container investment picks
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved BELSOMRA ® (suvorexant) for adults with insomnia who have difficulty falling asleep and/or staying asleep.
Sign-up for FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia investment picks
Covidien plc (NYSE: COV) today announced that the U.S. Food and Drug Administration (FDA) has approved changes to the manufacturing process for the polytetrafluoroethylene (PTFE) coating on the delivery wire of the company’s Pipeline™ embolization device.
Sign-up for FDA Approves Changes to Manufacturing Process for Covidien’s Pipeline™ Embolization Device investment picks
Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced that the U.
Sign-up for FDA Approves Eagle Pharmaceuticals’ Ryanodex® for the Treatment of Malignant Hyperthermia investment picks
First time in history a technology receives FDA approval and proposed national coverage by CMS on the same day Screening test detects 92% of colorectal cancer MADISON, Wis.
Sign-up for FDA Approves Exact Sciences' Cologuard®; First and Only Stool DNA Noninvasive Colorectal Cancer Screening Test investment picks
No. 1 Prescribed Allergy Treatment Ingredient(1) to be Available OTC PARSIPPANY, N.J. , July 24, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the U.S. Food and Drug Administration (FDA) has approved Flonase® Allergy Relief (fluticasone propionate 50 mcg spray), containing the No.
Sign-up for FDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: FBL Financial Group Declares Quarterly Dividend to FDA Approves Flonase® Allergy Relief For Sale Over-The-Counter In The United States
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices